Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3947 - Assessment and treatment of breakthrough cancer pain in Spain: a self-audit study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Rafael Lopez Lopez

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

R. Lopez Lopez1, J.J. Reina Zoilo2, D. Monge3, F. Caballero4, V. Guillem Porta5, E. Aranda Aguilar6, A. Carrato Mena7, E. Diaz Rubio8, J. Garcia Foncillas9, M. Feyjoo10, C. Camps11

Author affiliations

  • 1 Medical Oncology, Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, 15706 - Santiago de Compostela/ES
  • 2 Medical Oncology, Hospital Universitario Virgen Macarena, 41003 - Sevilla/ES
  • 3 Department Of Health Sciences, Francisco de Vitoria University, 28040 - Madrid/ES
  • 4 Department Of Health Sciences, Francisco de Vitoria University, 28014 - Madrid/ES
  • 5 Medical Oncology, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 6 Medical Oncology, University Hospital Reina Sofia, 14004 - Cordoba/ES
  • 7 Medical Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 8 Vicepresidente, Real Academia de Medicina, IdISCC, CIBERONC, 28040 - Madrid/ES
  • 9 Medical Oncology, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 10 Medical Oncology, Hospital Universitario La Moraleja, Sanitas, 28050 - Madrid/ES
  • 11 Medical Oncology, Consorcio Hospital General Universitario de Valencia, 46014 - Valencia/ES
More

Resources

Abstract 3947

Background

In Spain 77% of the episodes of Breakthrough cancer pain (BTcP), a common condition for cancer patients, are not properly diagnosed or treated. The ECO Foundation (Excellence and Quality in Oncology) has promoted this study with the collaboration of Francisco de Vitoria University, to compare the real-life clinical practice with the previous perception of the oncologists of the management of BTcP and to determine if clinical inertia exists in the approach of the BTcP episodes.

Methods

Observational and descriptive study consisting in two phases: a) opinion poll (self-completed online) answered by Spanish oncologists, and b) BTcP episodes screening and assesment (performed by the oncologist surveyed) in patients with a prior or current history of cancer pain (5 patients per oncologist). A recent expert consensus (1) and Davies algorithm were used to evaluate the correct diagnosis and optimal management of BTcP. A total of 108 oncologists participated in the study and 540 patients were evaluated.

Results

Although most oncologists (>80%) refer questioning their patients about the possibility of BTcP, only 34% of them do it systematically in their clinical practice. Most specialists believed that BTcP episodes were unlikely to go unnoticed in their consultations (62%). After evaluating real-life clinical practice, the overall prevalence of BTcP obtained was 91% (493/540). The doctors had previously detected the BTcP condition in 59% of patients (291/493), demonstrating that the under-diagnosis of BTcP exceeds 40%. In addition, 42% of patients with known BTcP were not able to control their episodes of pain and, despite the persistence, in 13% of them, no changes or adjustments had been made in the dose intensity or schedule.

Conclusions

The study confirms that there is a significant prevalence of BTcP and a notable inertia in the management of BTcP episodes, which seems to be poorly detected and treated in patients with cancer. Expanding the use of tools to diagnose BTcP, such as Davies algorithm, might be useful to improve the QoL of patients suffering pain.

Clinical trial identification

Legal entity responsible for the study

ECO Foundation.

Funding

Kyowa Kirin Pharmaceutical.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.